Table 4.
Demographic and clinical characteristics of patients enrolled in our study
| Characteristics | Vaccinated n = 441 | Non-vaccinated N = 120 | p value |
|---|---|---|---|
| Female gender, n (%) | 335 (75.9) | 89 (74.2) | 0.719 |
| Age, mean ± SD | 55.52 ± 14.48 | 50.28 ± 15.26 | 0.0008 |
| Smoking (current), n (%) | 122 (27.7) | 29 (24.2) | 0.487 |
| Disease | |||
| Inflammatory arthritis, n (%) | 258 (58.51) | 68 (56.7) | 0.668 |
| Connective tissue diseases, n (%) | 118 (26.8) | 36 (30.0) | |
| Autoinflammatory, n (%) | 16 (3.6) | 6 (5.0) | |
| Vasculitis, n (%) | 49 (11.1) | 10 (8.3) | |
| Disease duration (years), mean ± SD | 9.9 ± 8.3 | 10.3 ± 9.1 | 0.965 |
| College/university level of education, n (%) | 172 (39.0) | 38 (31.7) | 0.167 |
| Unemployment, n (%) | 72 (16.3) | 31 (25.8) | 0.023 |
| Treatment | |||
| On steroids, n (%) | 151 (34.2) | 48 (40.0) | 0.282 |
| On cDMARDs, n (%) | 287 (65.1) | 77 (64.2) | 0.915 |
| On b/tsDMARDs, n (%) | 245 (55.5) | 68 (56.7) | 0.917 |
Comparison between vaccinated and non-vaccinated patients
SD standard deviation, n number, cDMARDS conventional disease-modifying antirheumatic drugs, b/tsDMARDs biologic or targeted synthetic DMARDs